Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)
Primary Purpose
Cancer of Pancreas, Chemotherapy Effect, Metastatic Pancreatic Cancer
Status
Completed
Phase
Phase 2
Locations
Egypt
Study Type
Interventional
Intervention
Gemcitabine fluorouracil
Sponsored by
About this trial
This is an interventional treatment trial for Cancer of Pancreas focused on measuring pancreas, cancer, adenocarcinoma, metastatic, gemcitabine, flourouracil, chemotherapy, first line
Eligibility Criteria
Inclusion Criteria:
- Histopathological evidence of adenocarcinoma of the pancreas
- Radiological proof of metastatic disease as defined by AJCC
Exclusion Criteria:
- patients with poor performance status (ECOG 4)
- patients with organ dysfunction defined as: creatinine more than 1.6 mg/dl or bilirubin more than 3 mg/dl
- patients with end stage renal disease who are under regular dialysis
- other histologies of pancreatic cancer
- irresectable pancreatic cancer if not metatatic
Sites / Locations
- Menoufia University, Faculty of medicine
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Chemotherapy
Arm Description
Participants will receive the test protocol Gem-5FU on biweekly basis for 6 months with interim evaluation Doses as follows: Gemcitabine 1000 mg/m2, infusion over 30 min, D1, D15 Leucovorin 400 mg/m2 infusion over 30 min , D1, D15 5FU 400 mg/m2 I.V. shot D1, D15 5FU 2000 mg/m2 infusion over 46 hours D1 , D15
Outcomes
Primary Outcome Measures
Overall response rate (ORR)
describes according to RECIST criteria
Secondary Outcome Measures
Adverse events (AE)
Describes according to CTCAE
Progression free survival (PFS)
The time interval between the date of metastasis to the date of next disease progression
Overall survival (OS)
The time interval between the date of diagnosis till the date of death
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04769414
Brief Title
Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)
Official Title
A Phase II Trial of Flouro-Gem as a First Line Treatment of Metastatic Adenocarcinoma of the Pancreas (GEFLUPAN)
Study Type
Interventional
2. Study Status
Record Verification Date
August 2022
Overall Recruitment Status
Completed
Study Start Date
February 20, 2021 (Actual)
Primary Completion Date
July 9, 2022 (Actual)
Study Completion Date
July 9, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Menoufia University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this study, the investigators designed a treatment regimen including the most active agents in pancreatic cancer which are gemcitabine and fluorouracil to be tested as a first line treatment. This regimen is expected to be less toxic than FOLFIRINOX and aiming at better outcomes.
Detailed Description
Metastatic cancer pancreas has been a challenge for oncologists over the years. It is a disease of limited survival and a very poor response to treatment. The median overall survival at five years is expected to be between 4-6% only. Adenocarcinoma is the most common type of pancreatic cancer. It is the tenth most common adult solid malignancy. Most of the new therapeutic modalities has proven to be non-beneficial in this disease including targeted and immunotherapy.
For many years, the first line of treatment for pancreatic cancer was gemcitabine either alone or in combinations. Recently, FOLFIRINOX has become the standard of care due to its overall survival benefit. However, it is a small benefit on the expense of great toxicity.
Patients with metastatic cancer pancreas are recruited to receive the test regimen. Baseline evaluation will be done either by CT scan or PET/CT. re-evaluation will be repeated after 3 months of treatment and at end of 6 months
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer of Pancreas, Chemotherapy Effect, Metastatic Pancreatic Cancer
Keywords
pancreas, cancer, adenocarcinoma, metastatic, gemcitabine, flourouracil, chemotherapy, first line
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
48 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Chemotherapy
Arm Type
Experimental
Arm Description
Participants will receive the test protocol Gem-5FU on biweekly basis for 6 months with interim evaluation
Doses as follows:
Gemcitabine 1000 mg/m2, infusion over 30 min, D1, D15 Leucovorin 400 mg/m2 infusion over 30 min , D1, D15 5FU 400 mg/m2 I.V. shot D1, D15 5FU 2000 mg/m2 infusion over 46 hours D1 , D15
Intervention Type
Drug
Intervention Name(s)
Gemcitabine fluorouracil
Intervention Description
chemotherapy protocol given as:
Gemcitabine 1000mg/m2 IV short infusion
Leucovorin 400 mg/m2 IV short infusion
Flourouracil 400 mg/m2 direct IV shot
Flourouracil 2000 mg/m2 contineous infusion over 46 hours
The whole regimen will be repeated bi-weekly
Primary Outcome Measure Information:
Title
Overall response rate (ORR)
Description
describes according to RECIST criteria
Time Frame
6 months from enrollment
Secondary Outcome Measure Information:
Title
Adverse events (AE)
Description
Describes according to CTCAE
Time Frame
6 months from chemotherapy
Title
Progression free survival (PFS)
Description
The time interval between the date of metastasis to the date of next disease progression
Time Frame
One year from start of enrollment
Title
Overall survival (OS)
Description
The time interval between the date of diagnosis till the date of death
Time Frame
One year from start of enrollment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histopathological evidence of adenocarcinoma of the pancreas
Radiological proof of metastatic disease as defined by AJCC
Exclusion Criteria:
patients with poor performance status (ECOG 4)
patients with organ dysfunction defined as: creatinine more than 1.6 mg/dl or bilirubin more than 3 mg/dl
patients with end stage renal disease who are under regular dialysis
other histologies of pancreatic cancer
irresectable pancreatic cancer if not metatatic
Facility Information:
Facility Name
Menoufia University, Faculty of medicine
City
Shibīn Al Kawm
State/Province
Menoufia
ZIP/Postal Code
32511
Country
Egypt
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
IPD can be shared with other investigators upon personal contact with the PI of the study and after publishing the primary results. The investigators of this study are to be submitted as co-investigators in any other studies using the data of this study.
IPD Sharing Time Frame
After publishing the primary results of the study, expected to be by January 2023
Citations:
PubMed Identifier
21561347
Citation
Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.
Results Reference
background
Learn more about this trial
Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)
We'll reach out to this number within 24 hrs